In clinical chemotherapy of breast cancer, increased expression of Glo1 was associated with decreased patient survival, with hazard ratio HR = 1.82 where the upper quartile survival of patients was decreased 64% with high Glo1 expression; upper quartile overall survival decreased from ca. 15 to 5 years [20]. This evidence concerns the gene GLO1 and breast cancer.